Therapeutic fusion proteins
US10081803B2 · kind B2 · utility
2Cited by
5References
25Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 16, 2012 |
| Grant date | Sep 25, 2018 |
| Priority date | — |
| Expiry date | Dec 31, 2033 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/74
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to the construction of a new class of Targeted Secretion Inhibitors (TSIs), which comprise a non-cytotoxic protease, translocation peptide and a targeting moiety peptide, wherein the targeting moiety peptide has a free N-terminal domain and a free C-terminal domain; to a single-chain fusion protein precursor thereof, and to a method of activating said single-chain fusion protein precursor.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.